BPC-157

BPC-157 is a synthetic 15-amino-acid peptide taken from a sequence found in human gastric juice. Researchers studying how the stomach protects its own lining identified it in the 1990s [1]. What drew early attention was its apparent stability in stomach acid and what it appeared to do to healing in rats. Today it circulates mainly in recovery, biohacking and sports circles, on claims about tendon, gut and soft-tissue repair.

The evidence behind those claims is almost entirely preclinical — cells and rats, not people. Not one randomized controlled trial in humans has been completed and published for any indication. It is not on the FDA list of bulk substances that pharmacies may lawfully compound with, which is why licensed US pharmacies do not supply it. It now moves as an unregulated research chemical.

What follows is what the published literature actually supports, with animal-only findings labeled as such rather than blurred into human claims. Enthusiasm from recovery forums is anecdote, and it is worth being explicit that anecdote is not a weaker form of evidence here — it is a different thing altogether.

In animal models the proposed route runs through the nitric oxide system and through angiogenesis — new blood vessels growing into damaged tissue [4]. Interaction with VEGF pathways appears to be involved, along with some effect on nitric oxide synthase — which may account for part of the wound-healing signal rats show. In the gut, it has been studied for protecting the intestinal lining against damage from NSAIDs and other insults, apparently by holding the mucosal barrier together and damping local inflammation [2] [3].

For the musculoskeletal uses that drive most of the marketing, animal data suggest it may speed fibroblast proliferation and remodeling where tendon meets bone in rat injury models [5]. The molecular pathway is not fully characterized, and the distance between rat pharmacology and a human therapeutic effect is wide and entirely unvalidated [6].

Almost all of it comes from animals, and a striking share from one place. The literature originates largely with a single group at the University of Zagreb, which has run rat-model studies for three decades across protection of the stomach lining [1] [2], repair of tendon and ligament [5], and how blood vessels behave [4]. Those studies are internally consistent and mechanistically interesting. They remain animal data.

A 2026 translational review in Pharmaceutics calls it an investigational peptide therapeutic and identifies the thing that matters most: no completed Phase I or Phase II human trial exists at all, which is a fundamental barrier rather than a gap waiting to be filled [6]. The review also catalogs formulation and biopharmaceutical problems that complicate getting to human studies in the first place.

An independent 2026 review in Sports Medicine assessed approved and unapproved peptides in musculoskeletal injury and athletic performance. It concluded the human evidence for this one is insufficient to support recommending it to patients or athletes [7].

Evidence grade C, preclinical only. Every online claim about tendon repair, gut healing or recovery in people is an extrapolation from rodents. And the extrapolation has had three decades to be tested and has not been — which is itself information about how hard the translation is turning out to be.

There is no established human dose, because there are no completed human trials to establish one. Rodent work has used roughly 2 to 10 mcg per kg of body weight, given under the skin or into the stomach. The research-chemical market commonly quotes 200 to 500 mcg a day by subcutaneous injection, or oral capsules around the same, and those numbers rest on no validated human pharmacokinetic or pharmacodynamic basis whatsoever.

Oral versions are widely sold. The argument for them is that the peptide holds up in stomach acid, which might support some absorption — though absorption data in humans do not exist to check that against. BPC-157 is not on the FDA list of bulk substances that pharmacies may compound with, so licensed US pharmacies have no lawful route to supply it, and what fills the gap sells it as a research chemical explicitly not meant for people.

Nobody knows the long-term safety profile in humans. Rat studies have not turned up outright organ toxicity at the doses tested, and rodent safety is not a dependable proxy for human safety with complex peptides. The 2026 Sports Medicine review made the point that unapproved peptides carry risk from the supply chain itself — unregulated manufacturing, unknown purity, and no pharmacovigilance data at all [7]. What arrives in a vial bought online may be the wrong dose, may be impure, or may be a different sequence than the label claims.

On the regulatory side: BPC-157 is not on the 503A Bulks List, the list of bulk drug substances a pharmacy may lawfully compound with, and it is neither a USP monograph substance nor a component of any approved drug — the three routes the statute allows. Both nominations to that list were withdrawn by the companies that filed them, and the FDA is now evaluating the substance on its own initiative. Its May 2026 briefing document for the Pharmacy Compounding Advisory Committee recommends against adding it, citing inconsistent chemical characterization, missing data on peptide impurities and aggregates, and the risk that an injectable form provokes an immune response. It is approved for no human indication. Outside an IRB-approved trial, use is unregulated and the risks cannot be quantified — not because they are known to be small, but because the human safety data that would quantify them does not exist.